Extra indication for VivaGel
Wednesday, 09 July, 2008
Melbourne biotech Starpharma [ASX: SPL] has announced plans to adapt the development of its vaginal microbicide VivaGel to incorporate the treatment of bacterial vaginosis.
VivaGel is currently in clinical trials as a prevention against the viruses such as HIV, genital herpes (HSV) and genital warts (HPV), and as a potential contraceptive. This is the first indication for which VivaGel might be used as a treatment.
Early tests suggest that VivaGel is able to reverse the imbalance between vaginal lactobacilli and disease-causing bacteria which is a characteristic of the condition.
Bacterial vaginosis is a major cause of vaginal infection, is implicated in pelvic inflammatory disease and may be associated with an increased risk of STIs and abortion.
Starpharma CEO Dr Jackie Fairley said the application was of interest because of its potential to open up new and rapid paths to market for VivaGel.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
